eyenovia-logo 3

2015 News Releases

Keyword Search
2019 | 2018 | 2017 | 2016 | 2015
Eyenovia Biopharma Signs Exclusive Asia License and Development Agreement for Ophthalmic Therapeutics Based on Proprietary Microdrops Technology
Eyenovia's Smart Microdose Technology Targets the $19Bn Global Ophthalmic Pharmaceutical Market With a Portfolio of Microdrops of Existing and New Formulations With Improved Therapeutic ProfileTAMPA, FL--(Marketwired - April 15, 2015) - Eyenovia, Inc. ("Eyenovia"), a clinical-stage specialty pharmaceutical company building an ophthalmic portfolio of microdosed therapeutics, today announced the signing of an exclusive license and development agreement with Senju Pharmaceutical Co., Ltd. ("Se... 

Contact us for more information

Contact us today to learn more about how our microdosing technology is poised to transform
the standard of care in ophthalmic therapeutic delivery.

New York    501 Fifth Avenue, Suite 1404 New York NY 10017     +1 (917) 289-1117

[email protected]